Helius Therapeutics
Mary Alice Simon has a diverse work experience spanning multiple industries. Mary Alice is currently working as the Chief Operating Officer at Helius Therapeutics since February 2021. Prior to this, they worked at API Consumer Brands as an Operations Manager from August 2019 to December 2020 and as the Head of Quality from July 2015 to July 2019. Before joining API Consumer Brands, Mary Alice was employed at Diatranz Otsuka Limited, where they served as the Head of Quality Assurance from April 2014 to July 2015 and as the Manager of Quality Assurance from January 2012 to April 2014. Mary Alice started their career at Penobscot Community Health Care as the Director of Data Management from January 2007 to February 2012.
Mary Alice Simon has a Bachelor of Science degree in Biochemistry from Virginia Tech, which they earned from 1988 to 1992. Mary Alice then pursued a Master of Science degree in Microbiology from the same institution, which they completed between 1992 and 1994. Later, Mary Alice attended the University of Maine from 2008 to 2012, where they obtained a Master of Business Administration (MBA) degree. No specific field of study was mentioned for their MBA program.
Helius Therapeutics
8 followers
Helius is a New Zealand-owned biotechnology company focused on medicinal cannabis research and development. The country’s largest licensed producer and the first medicinal cannabis cultivator to be certified as New Zealand Grown through Buy NZ Made Campaign, Helius a leader in this nascent market. The company operates a state-of-the-art GMP facility in Auckland with indoor controlled growing systems, integrated extraction site, an advanced cannabinoid research laboratory and manufacturing operations. Following changes in New Zealand’s regulatory environment, Helius is poised to set the standard for effective and accessible medicinal cannabis products.